Xu Bin, Xing Jin, Wu Wenqing, Zhang Wen-Jing, Zhu Qian-Qian, Zhang Dan, Sun Nan-Nan, Wu Chan, Kang Geng-Jie, Zhai Lin, Li Wei-Dong, Meng Yan, Du Tie-Ying
Department of Neurology, Fuxing Hospital, Capital Medical University, Beijing 100038, P.R. China.
Department of Ultrasound, Fuxing Hospital, Capital Medical University, Beijing 100038, P.R. China.
Exp Ther Med. 2018 May;15(5):4491-4497. doi: 10.3892/etm.2018.5926. Epub 2018 Mar 6.
The present study assessed changes in carotid plaque neovascularization following long-term atorvastatin therapy (20 mg/day) using contrast-enhanced ultrasonography (CEUS). In this prospective case series, seven males (mean age, 68±9 years) and three females (mean age, 67±10 years) with a total of 13 carotid plaques underwent standard ultrasonography and CEUS at baseline, as well as after 1 and 2 years of atorvastatin treatment. The same plaques were then examined using real-time CEUS. The results of the enhanced intensity of plaque neovascularization at baseline were compared with results obtained during follow-up to examine the effects of long-term atorvastatin therapy. Standard ultrasonography revealed that 7 of the 13 carotid plaques were uniformly echolucent, whereas 6 carotid plaques were predominantly echolucent. CEUS revealed an enhanced intensity of 10.5±2.1 decibels (dB) prior to treatment, which decreased significantly to 7.3±2.6 dB following 2 years atorvastatin therapy (P<0.001). The ratio of enhanced intensity in the carotid artery lumen to that in the plaque was 3.10±1.10 at baseline and this value significantly increased to 4.96±2.98 following treatment for 2 years (P<0.001). The current pilot study therefore indicates that two-year atorvastatin therapy (20 mg/day) may reduce plaque neovascularization in the Chinese population.
本研究使用超声造影(CEUS)评估长期阿托伐他汀治疗(20毫克/天)后颈动脉斑块新生血管的变化。在这个前瞻性病例系列中,7名男性(平均年龄68±9岁)和3名女性(平均年龄67±10岁),共13个颈动脉斑块在基线时以及阿托伐他汀治疗1年和2年后接受了标准超声检查和CEUS检查。然后使用实时CEUS对相同的斑块进行检查。将基线时斑块新生血管增强强度的结果与随访期间获得的结果进行比较,以研究长期阿托伐他汀治疗的效果。标准超声检查显示,13个颈动脉斑块中有7个均匀无回声,而6个颈动脉斑块主要为无回声。CEUS显示治疗前增强强度为10.5±2.1分贝(dB),阿托伐他汀治疗2年后显著降至7.3±2.6 dB(P<0.001)。颈动脉管腔与斑块中增强强度的比值在基线时为3.10±1.10,治疗2年后该值显著增加至4.96±2.98(P<0.001)。因此,目前的初步研究表明,两年的阿托伐他汀治疗(20毫克/天)可能会减少中国人群中的斑块新生血管。